Stockscreener 앱 받기
28.75
2.06%
0.58
Sanuwave Health Inc 주식(SNWV)의 최신 뉴스
Sanuwave Health to uplist to the Nasdaq Global Market - MSN
AllPennyStocks.com News: Sanuwave Looking Over the Shoulder of Competitors in the Diabetic Foot Ulcer Industry - ACCESS Newswire
Why We're Not Concerned About SANUWAVE Health, Inc.'s (NASDAQ:SNWV) Share Price - Simply Wall St
SANUWAVE Health (NASDAQ:SNWV) shareholder returns have been splendid, earning 278% in 1 year - Yahoo Finance
Sanuwave Health to Uplist to the Nasdaq Global Market - OrthoSpineNews
Sanuwave Health Secures Coveted Nasdaq SpotWhat This Means for SNWV Investors - StockTitan
Can This Regenerative Medicine Pioneer Transform the $50B Wound Care Market? Key Investor Conference Ahead - StockTitan
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results - GlobeNewswire
SANUWAVE Will Host a Conference Call on November 8, 2024 at 8:30 AM (ET) to Present Q3 Financial Results - GlobeNewswire
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering - Yahoo Finance
Sanuwave Health announces 1-for-375 reverse stock split - Yahoo Finance
SANUWAVE Health Announces 1-For-375 Reverse Stock Split - StockTitan
SANUWAVE Will Host a Conference Call on May 10, 2024 at 8:30 AM (ET) to Present Q1 Financial Results - The Globe and Mail
SANUWAVE Health Appoints Industry Veteran Peter Sorensen as Chief Financial Officer - GlobeNewswire
Eden Prairie-based Sanuwave Health seeks Nasdaq listing in SPAC deal - Star Tribune
SANUWAVE signs merger agreement with SEPA - Medical Device Network
SANUWAVE Health, Inc., a Leading Provider of FDA Approved - GlobeNewswire
Sanuwave appoints new CEO - Mass Device
SANUWAVE Health, Inc. Appoints Morgan Frank as Chief Executive Officer - GlobeNewswire
SANUWAVE Health to Host Conference Call and Provide Business Update - The Globe and Mail
Sanuwave announces intent to acquire Celularity’s UltraMist - Mass Device
Sanuwave partners with The Mobile Health Company - Mass Device
Sanuwave Health inks dev deal with eKare for wound care integration - Mass Device
Sanuwave files for de novo FDA nod for DermaPace wound care device - Mass Device
Sanuwave trial misses efficacy endpoint but shows superiority at 24 weeks - Mass Device
2.18%
자본화:
|
볼륨(24시간):